CTI BIOPHARMA CORP Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Cti Biopharma Corp quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q1 2023.
  • Cti Biopharma Corp Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2023 was -$13.4M, a 63.9% increase year-over-year.
  • Cti Biopharma Corp Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2023 was -$69.2M, a 41.2% increase year-over-year.
  • Cti Biopharma Corp annual Net Income (Loss) Attributable to Parent for 2022 was -$93M, a 5.02% increase from 2021.
  • Cti Biopharma Corp annual Net Income (Loss) Attributable to Parent for 2021 was -$97.9M, a 86.7% decline from 2020.
  • Cti Biopharma Corp annual Net Income (Loss) Attributable to Parent for 2020 was -$52.5M, a 31.1% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 -$69.2M -$13.4M +$23.8M +63.9% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-15
Q4 2022 -$93M -$17.5M +$19.3M +52.5% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-06
Q3 2022 -$112M -$15.7M +$8.47M +35% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-07
Q2 2022 -$121M -$22.7M -$2.98M -15.1% Apr 1, 2022 Jun 30, 2022 10-Q 2022-11-07
Q1 2022 -$118M -$37.2M -$19.9M -115% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$97.9M -$36.8M -$21.8M -145% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-06
Q3 2021 -$76.1M -$24.2M -$12.9M -115% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$63.2M -$19.7M -$5.68M -40.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$57.5M -$17.3M -$5.08M -41.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$52.5M -$15M -$6.81M -83.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$45.6M -$11.3M -$1.22M -12.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$44.4M -$14M -$3.03M -27.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 -$41.4M -$12.2M -$1.37M -12.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 -$40M -$8.19M -$9.03M -1068% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-17
Q3 2019 -$31M -$10M +$4.76M +32.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$35.7M -$11M +$365K +3.22% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-10
Q1 2019 -$36.1M -$10.8M -$6.79M -169% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-10
Q4 2018 -$29.3M $846K +$15.1M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-13
Q3 2018 -$44.4M -$14.8M -$2.84M -23.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-04
Q2 2018 -$41.6M -$11.3M -$16.7M -310% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-04
Q1 2018 -$24.9M -$4.02M +$15.8M +79.7% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-04
Q4 2017 -$40.7M -$14.3M -$7.89M -124% Oct 1, 2017 Dec 31, 2017 10-K 2018-03-07
Q3 2017 -$32.8M -$12M +$17.2M +59% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 -$50M $5.4M +$25.2M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-03
Q1 2017 -$75.1M -$19.8M -$23.1M -699% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 -$52M -$6.37M +$19.3M +75.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-03-07
Q3 2016 -$71.3M -$29.2M +$3.41M +10.5% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-07
Q2 2016 -$74.7M -$19.8M +$12.8M +39.4% Apr 1, 2016 Jun 30, 2016 10-K 2018-03-07
Q1 2016 -$87.5M $3.31M +$31.9M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-07
Q4 2015 -$119M -$25.6M +$15.9M +38.3% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-02
Q3 2015 -$135M -$32.6M -$37.2M -808% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-02
Q2 2015 -$98.2M -$32.6M -$5.2M -19% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-02
Q1 2015 -$93M -$28.6M +$405K +1.4% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-02
Q4 2014 -$93.4M -$41.6M -$51.8M -508% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-17
Q3 2014 -$41.6M $4.6M +$20.1M Jul 1, 2014 Sep 30, 2014 10-K 2016-02-17
Q2 2014 -$61.7M -$27.4M -$9.39M -52.1% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-17
Q1 2014 -$52.4M -$29M -$9.62M -49.6% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-17
Q4 2013 -$42.7M $10.2M +$28.8M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-12
Q3 2013 -$71.5M -$15.5M -$355K -2.34% Jul 1, 2013 Sep 30, 2013 10-K 2015-03-12
Q2 2013 -$71.2M -$18M +$32.1M +64.1% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-12
Q1 2013 -$103M -$19.4M -$1.94M -11.1% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-12
Q4 2012 -$101M -$18.6M -$9.63M -107% Oct 1, 2012 Dec 31, 2012 10-K 2014-03-04
Q3 2012 -$91.7M -$15.2M +$1.47M +8.84% Jul 1, 2012 Sep 30, 2012 10-K 2014-03-04
Q2 2012 -$93.2M -$50.1M -$33.1M -195% Apr 1, 2012 Jun 30, 2012 10-K 2014-03-04
Q1 2012 -$60.1M -$17.4M +$2.29M +11.6% Jan 1, 2012 Mar 31, 2012 10-K 2014-03-04
Q4 2011 -$62.4M -$8.97M Oct 1, 2011 Dec 31, 2011 10-K 2013-02-28
Q3 2011 -$16.7M -$4.14M -33.1% Jul 1, 2011 Sep 30, 2011 10-K 2013-02-28
Q2 2011 -$17M +$6.49M +27.6% Apr 1, 2011 Jun 30, 2011 10-K 2013-02-28
Q1 2011 -$19.7M Jan 1, 2011 Mar 31, 2011 10-K 2013-02-28
Q3 2010 -$12.5M Jul 1, 2010 Sep 30, 2010 10-Q 2011-10-25
Q2 2010 -$23.5M Apr 1, 2010 Jun 30, 2010 10-Q 2011-07-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.